Tuesday, January 12, 2016 8:29:40 AM
The biotech business (and as a startup here) is hard to handicap as they are bringing assets along and having them mature like a fine wine (hence...without the proper funding). Each day going forward...could see a monumental announcement that triples or quadruples the stock price.
They have to monetize somewhere in the pipeline:
a) Gene therapy - partnerships via Wallachbeth investment firm
b) eltoprazine - partnership via a pharma. or investment firm
c) DX Transaction - spin out
d) Venture capital - its the latter here which intrigues me as to why there hasnt been any investments from these types of firms. Or MJFF.
e) Govt funding - DOJ....grants.
f) Govt vouchers - the holy grail...in my opinion. for Rare diseases.
So many opportunities to find $$$...hard to figure why its always taking so long.
Note to Gerald ..you work for the shareholders (not your personal agenda).
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM